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Background: LiHyV is an antigenic hypothetical protein present in both promastigote and amastigote stages of
Leishmania infantum, which was recently identified by an immunoproteomic approach. A recombinant version of this
protein (rLiHyV) was evaluated as a diagnostic marker for canine VL (CVL). In addition, the prophylactic efficacy of the
rLiHyV protein, and two of its CD8+ T cell epitopes, has been analyzed in a murine model of visceral leishmaniasis (VL).
Methods: Initially, the rLiHyV protein was evaluated by an ELISA technique for the serodiagnosis of CVL. Secondly,
vaccines composed of the recombinant protein and both chemically synthesized peptides, combined with saponin as
an adjuvant; were administered subcutaneously into BALB/c mice. The cellular and humoral responses generated by
vaccination were evaluated. In addition, the parasite burden and immune response were studied 10 weeks after L.
infantum infection.
Results: The rLiHyV protein was recognized by antibodies of VL dogs. No cross-reactivity was obtained with sera from
dogs vaccinated with a Brazilian commercial vaccine, with sera from animals infected with Trypanosoma cruzi, Babesia
canis and Ehrlichia canis, or those from non-infected animals living in an endemic area for leishmaniasis. After challenge
with L. infantum, spleen cells of BALB/c mice vaccinated with rLiHyV/saponin stimulated with parasite antigens showed
a higher production of IFN-γ, IL-12 and GM-CSF, than the same cells obtained from mice vaccinated with the individual
peptides, or mice from control (inoculated with saline or saponin) groups. This Th1-type cellular response observed in
rLiHyV/saponin vaccinated mice was accompanied by the induction of parasite-specific IgG2a isotype antibodies.
Animals immunized with rLiHyV/saponin showed significant reductions in the parasite burden in the liver, spleen, bone
marrow and in the lymph nodes draining the paws relative to control mice.
Conclusions: The present study showed for the first time that the L. infantum LiHyV protein could be considered as a
vaccine candidate against L. infantum infection, as well as a diagnostic marker for CVL.
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Leishmaniasis comprises a spectrum of diseases caused
by protozoan parasites of the genus Leishmania, which
presents a high morbidity and mortality in the world
[1]. About 350 million people are at risk of contracting
the infection in 98 countries, where 1.0 to 1.5 million
new cases of cutaneous leishmaniasis (CL), and 200,000
to 500,000 new cases of visceral leishmaniasis (VL) are
registered annually [2]. The treatment of disease is
based on the parenteral administration of pentavalent
antimonials, however, increased parasite resistance and
side effects observed in the patients have been import-
ant problems [3, 4]. Other drugs, such as amphotericin
B and its liposomal formulations, pentamidine and mil-
tefosine are encouraging, however, their toxicity and/or
high cost had limited their use [5, 6].
Canine visceral leishmaniasis (CVL) due to Leishmania
infantum is a major global zoonosis, which is endemic in
approximately 70 countries worldwide [7, 8]. It cannot
only be considered as a veterinary disease, since infected
dogs are the main domestic reservoirs of parasites for
human disease [7]. In this context, and aiming to reduce
the transmission of parasites between dogs and humans,
one could suggest that it is necessary to diagnose CVL as
early as possible. The Brazilian Public Health authorities
determine that, to a precise immunological diagnosis of
CVL, serological tests, such as IFAT and ELISA, should be
employed for the effective serodiagnosis of disease [9].
However, ELISA is hampered by some factors, such as by
variable specificity when different antigenic preparations
are employed, which can lead to the occurrence of false-
positive results caused by related pathogens, such as Try-
panosoma cruzi [10, 11], Ehrlichia canis and Babesia canis
[12]; or in vaccinated dogs [13]. In addition, its sensitivity
presents problems, mainly related to the fact that a high
percentage of infected dogs present low antileishmanial
serology, and they are classified as false-negative in the
serological assays performed; depending on the nature of
the antigen employed in the assay [13]. Therefore, the
development of new strategies to diagnose leishmaniasis
has become a priority.
Studies to evaluate vaccine candidates against leishman-
iasis have demonstrated the need to develop a Th1 cell-
mediated immune response, which is based on the pro-
duction of cytokines, such as IFN-γ, IL-12, and others
[14–19]. The induction of CD4+ Th1 cells specific to para-
site proteins is crucial in controlling the infection caused
by Leishmania spp. Cytokines such as IFN-γ are able to
induce the production of nitric oxide and other com-
pounds by infected phagocytic cells, thereby assisting in
the control of parasites’ multiplication [20, 21]. By oppos-
ite, cytokines such as TGF-β, IL-4, IL-10, and IL-13 repre-
sent important disease promoting substances, leading to
the suppression of Th1 response [22, 23]. Concomitantlyto the role of CD4+ T cells, the cytotoxic activity per-
formed by CD8+ T cells also contributes to protection
against VL. These cells has been shown to protect against
re-infection, as well as having a significant role in control-
ling the primary infection against Leishmania spp., by in-
creasing the Th1 immune response [19, 24–26].
Protozoan parasites of the genus Leishmania have a
dimorphic asexual life cycle consisting of extracellular
promastigotes, which multiply and develop within the
alimentary tract of the sand fly vector, and intracellular
amastigotes that multiply within the phagolysosomes of
the macrophages of the mammal hosts [27]. In addition,
most of the studies on Leishmania spp. vaccines have
focused in the use of promastigote proteins [28]. Amas-
tigote antigens have been far less evaluated as vaccine
candidates against disease. However, these forms seem
to be the more appropriate targets for the immune
responses elicited by a vaccine, since after a few hours of
initial infection and during the active disease, only the
amastigote stage is present in the infected host tissues.
In addition, in opposition to promastigotes, amastigotes
reside inside host cells, and can be targets for CD8+ T
cells [29, 30].
In the present study, the antigenic and immunoprophy-
lactic properties of a recently described parasite protein
have been studied. The Leishmania-specific hypothetical
protein, LiHyV (NCBI accession number: XP_888524.1),
was described as an antigen present in both promastigote
and amastigote stages of L. infantum by an immunopro-
teomic approach [31]. A recombinant version of the
LiHyV protein (rLiHyV) was evaluated as a diagnostic
marker for CVL. In addition, the rLiHyV protein and two
peptides containing two of its CD8+ T cells predicted epi-
topes were evaluated as vaccine candidates in a murine
model of VL.
Methods
Ethics statement
All technical protocols using mice and dogs’ sera in
the present study were performed in compliance with
the National Guidelines of the Institutional Animal
Care and Committee on the Ethical Handling of Re-
search Animals (CEUA) from the Federal University
of Minas Gerais (UFMG), which approved this study
with the code number 043/2011.
Mice and parasites
Female BALB/c mice (8 weeks age) were obtained from
the breeding facilities of the Department of Biochemistry
and Immunology, Institute of Biological Sciences (ICB),
Federal University of Minas Gerais (UFMG); and were
maintained under specific pathogen-free conditions.
Leishmania infantum (MHOM/BR/1970/BH46) strain
was used. Parasites were grown at 24 °C in Schneider’s
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plemented by 20 % heat-inactivated fetal bovine serum
(FBS, Sigma-Aldrich, USA), 20 mM L-glutamine, 200 U/
mL penicillin, and 100 μg/mL streptomycin, at pH 7.4.
The soluble L. infantum antigenic extract (SLA) was
prepared from stationary-phase promastigotes of para-
sites, as previously described [32].
Canine sera
The sample size of dogs’ sera consisted of 73 domestic ani-
mals (Canis familiaris), made up of males and females of
different breeds and ages. Sera of CVL were selected on
the basis of two Leishmania spp. serological tests (IFAT
[IFAT- LVC Bio-Manguinhos kit] and ELISA [EIE-LVC
Bio-Manguinhos kit], both from Biomanguinhos, Fiocruz,
Brazil). Dogs with an IFAT titer < 1/40 or ELISA reactivity
below the cut-off value indicated by the manufacturer
were considered to be serologically seronegative. Animals
with an IFAT titer > 1/40 and an ELISA value over the
cut-off were considered to be serologically seropositive.
Thus, symptomatic VL dogs (n = 16) were those positive
by IFAT and ELISA, and presenting three or more of the
following clinical symptoms: weight loss, alopecia, adeno-
pathy, onychogryposis, hepatomegaly, conjunctivitis and
exfoliative dermatitis on the nose, tail, and ear tips. In
addition, all dogs presented positive parasitological results
(PCR detection of L. infantum DNA). Non-infected dogs
(n = 20) were selected from an endemic area of leishman-
iasis (Belo Horizonte, Minas Gerais, Brazil), but presenting
negative serological and parasitological results, as well as
were free of any clinical suspicion or signals of leishmania-
sis. Also, sera samples of non-infected animals immunized
with a Brazilian commercial vaccine (Leish-Tec®) (n = 10),
which were isolated in kennels to prevent their contact
with transmitting vectors of leishmaniasis, were used. In
addition, sera of dogs experimentally infected with T. cruzi
(n = 13), Ehrlichia canis (n = 7) or Babesia canis (n = 7)
were also used in the ELISA assays, in order to evaluate
the cross-reactivity. These sera samples were obtained
from previous projects, which evaluated the immune re-
sponse in the infected animals [15, 33, 34]. Serum samples
were provided by Prof. Maria Norma Mello (Department
of Parasitology, UFMG, Belo Horizonte, Brazil), and Prof.
Ana Paula Fernandes (Department of Clinical and Toxico-
logical Analysis, UFMG, Belo Horizonte, Brazil).
Cloning of DNA sequence coding for L. infantum
hypothetical protein, LiHyV
The LiHyV (XP_888524.1) nucleotide and amino acid
sequences were obtained from the National Center for
Biotechnology Information (http//www.ncbi.nlm.nih.gov).
The local alignment of the protein sequence against the
available complete genomes of other organisms was per-
formed by BLAST, which verified a high homology ofamino acid sequence (>85 %) of this protein among the
L. major, L. amazonensis and L. infantum species. The
recombinant protein was obtained after cloning a L. infan-
tum (MHOM/BR/1970/BH46) DNA fragment containing
the protein-coding region. Initially, genomic DNA was
extracted using a phenol:chloroform extraction, and
this was used as a template. The forward (5′-GACG
GATCCATGTCGGACGCATCATTC-3′) and reverse (5′-
GCACAAGCTTAAGGGCGTAGAAAGCGGC-3′) primers
were designed according to the DNA sequence of the
\ORF described in the L. infantum genome sequence data-
base (LinJ. 04.0160). The PCR product was cloned into
the pGEM-T easy vector confirmed by sequencing and
transferred to the pET21a expression vector (Novagen),
using the BamHI and HindIII restriction enzymes in-
cluded in the primers for this purpose (underlined). Re-
combinant plasmid was transformed into Escherichia coli
BL21 (DE3). The recombinant protein expression was
performed by adding 1.0 mM IPTG (isopropyl-β-D-thio-
galactopyranoside, Promega, Montreal, Canada), for 3 h at
37 °C, when cells were lysed by a homogenizer after five
passages through the apparatus. The product was centri-
fuged at 13,000 × g for 20 min at 4 °C, while the rLiHyV
protein, containing a tag of 6x residues of histidine, was
purified under non-denaturing conditions, using a 5 mL
HIS-Trap column (GE Healthcare Life Science) attached
to an FPLC (GE Healthcare Life Science) system. After
purification, the recombinant protein content was passed
through a polymyxin-agarose column (Sigma), in order to
remove residual endotoxins. The recombinant protein A2
was cloned and purified as previously described [32].
In silico prediction of T-cell epitopes
The linear CD8+ T cells epitopes of LiHyV protein were
predicted using BIMAS software (www-bimas.cit.nih.gov/
molbio/hla_bind/), where peptides that presented a score
higher than 100.0 were selected to be evaluated as vaccine
candidates against VL. Two amino acid sequences were
synthesized to be employed in the vaccination experiments:
AGQSVPNSL (Peptide1) and VGIKNTAALFVLNATAI
(Peptide2). The second peptide was originally composed of
two different peptides (VGIKNTAAL and LFVLNATAI),
which presented the best results of in silico prediction of
CD8+ T cell epitopes in the analysis, besides a sequential
position in the primary sequence of amino acids of the
LiHyV protein. So, the peptides were commercially synthe-
sized (Genscript®, USA)”.
ELISA for the serodiagnosis of CVL
Previous titration curves were performed to determine the
most appropriate antigen concentration and antibody dilu-
tion to be used. The recombinant LiHyV and A2 proteins,
as well as SLA L. infantum-specific IgG antibodies were
evaluated. For this, microtiter immunoassay plates (Falcon)
Martins et al. Parasites & Vectors  (2015) 8:363 Page 4 of 12were coated with rLiHyV, rA2 or SLA (1.0, 0.5 and 1.0 μg
per well, respectively), diluted in 100 μL of coating buffer
(50 mM carbonate buffer pH 9.6), for 18 h at 4 °C. The
experimental protocol used in the ELISA assays was devel-
oped as previously described [21]. In addition, all sera
samples were evaluated in the same day using the same
reagents (lots, dilutions, etc.), aiming to reduce or eliminate
the possible experimental variations and the interference in
the interpretation of data that could occur if the ELISA
assays had been performed on different days.Fig. 1 Diagnostic performance of LiHyV protein. ELISA assays were performed u
dogs living in an endemic area of leishmaniasis (n= 20), Leish-Tec®-vaccinated a
(n= 13), Ehrlichia canis (n= 7) or Babesia canis (n= 7). The rLiHyV (a), SLA L. infan
of each individual serum are shown. The cut-off values (dotted line) for negative
times the standard deviation of all negative samples. The sensitivity and specificImmunization and challenge infection
Mice (n = 8, per group) were vaccinated subcutaneously
in their left hind footpad with 25 μg of rLiHyV, Pep-
tide1 or Peptide2, all associated with 25 μg of saponin
(Quillaja saponaria bark saponin, Sigma); or received
saponin or saline. Three doses were administered at
two-week intervals. Four weeks after the third and last
immunization, animals (n = 4, per group) were euthanized
to analyze the immune response elicited by vaccination.
At the same time, the remaining animals were infectedsing sera samples of dogs with visceral leishmaniasis (n= 16), non-infected
nimals (n= 10) and animals experimentally infected by Trypanosoma cruzi
tum (b), and rA2 (c) were used as antigens. The optical density (O.D.) values
and positive sample discrimination were calculated using the mean ± three
ity values of the antigens were calculated and are also showed (d)
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tionary-phase promastigotes of L. infantum. Ten weeks
after infection, animals were euthanized and the spleen,
liver, bone marrow (BM), and lymph nodes draining the
paws (dLN) of the animals were collected to evaluate the
immune response and parasite burden. Vaccination exper-
iments were repeated twice and presented similar results.
Estimation of parasite burden
The liver, spleen, BM, and dLN were collected for para-
site quantification, following a limiting-dilution tech-
nique, as previously described [19].
Cytokine production before and after L. infantum
infection
Splenocyte cultures and cytokine assays were performed
after the last immunization and before infection, as well as
at the 10th week after challenge. For this, single-cell sus-
pensions were plated in duplicate in 24-well plates (Nunc),Fig. 2 Immune response induced by immunization with rLiHyV protein plus sa
weeks after the last immunization and before infection. Cells were unstimulated
group, 20 μg/mL), Peptide1 (Peptide1/saponin group, 20 μg/mL) or Peptide2 (P
stimulated with SLA (25 μg/mL). IFN-γ, IL-12, GM-CSF, IL-4, and IL-10 levels were
from animals immunized with rLiHyV/saponin and stimulated with rLiHyV, Pept
observed between negative control (medium), SLA, Peptide1 and Peptide2 (a, b
as between IL-12/IL-10 and IL-12/IL-4 (d). Bars represent the mean ± standard de
to the saline, saponin or rLiHyV/saponin groups were observed (a, b and c respeat 1 × 106 cells per mL. Cells were incubated in RPMI 1640
medium (negative control), which was supplemented with
10 % FBS, 20 mM L-glutamine, 200 U/mL penicillin, and
100 μg/mL streptomycin, at pH 7.4; or separately stimu-
lated with rLiHyV, Peptide1, Peptide2 or L. infantum SLA
(20, 25, 25, or 25 μg mL−1, respectively); for 48 h at 37 °C
in 5 % CO2. IFN-γ, IL-4, IL-10, IL-12, and GM-CSF levels
were assessed in the supernatants by a sandwich ELISA
provided in commercial kits (BD OptEIA TM set mouse
IFN-γ, IL-4, IL-10, IL-12, and GM-CSF; all obtained from
Pharmingen, San Diego, CA, USA); following manufac-
turer’s instructions. In order to block IL-12, CD4+, and
CD8+ mediated T cell cytokine release, spleen cells of mice
vaccinated with rLiHyV/saponin and challenged with L.
infantum were in vitro stimulated with SLA (25 μg mL−1),
and incubated in the presence of 5 μg mL−1 of
monoclonal antibodies (mAb) against mouse IL-12
(C17.8), CD4 (GK 1.5), or CD8 (53–6.7). Appropriate
isotype-matched controls – rat IgG2a (R35-95) andponin. Single cells suspensions were obtained from the spleen of mice, four
(negative control), or separately stimulated with rLiHyV (rLiHyV/saponin
eptide2/saponin group, 25 μg/mL). Saline and saponin groups were
measured by a capture ELISA (a). Cytokine levels of spleen cells derived
ide1, Peptide2 or SLA (b). Statistically significant differences (P< 0.001) were
, c, and d, respectively) and in ratios of IFN-γ/IL-10 and IFN-γ/IL-4 (c), as well
viation of the groups. Statistically significant differences (P< 0.05) in relation
ctively)
Fig. 3 Humoral response induced by vaccination with rLiHyV
protein plus saponin. Sera samples were collected from animals four
weeks after the third and last immunization, and before infection.
The parasite-specific IgG1 (a) and IgG2a (b) isotype levels were
determined, and the bars represent the mean ± standard deviation
of the groups. The ratios between IgG2a and IgG1 levels were also
calculated (c). Statistically significant differences in relation to the
saline, saponin or rLiHyV/saponin groups were observed (a, b and c
letters, respectively; P < 0.05)
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Antibodies (no azide/low endotoxin™) were purchased
from BD (Pharmingen).
Evaluation of the humoral response
The antibody production was evaluated after the third
and last immunization and before infection, as well as at
the 10th week after challenge. The parasite-specific IgG1
and IgG2a isotype antibody levels were measured by an
ELISA technique, as previously described [19].
Statistical analysis
The results were entered into Microsoft Excel (version
10.0) spreadsheets, and analyzed using GraphPad Prism™
(version 6.0 for Windows). The mean optical density
(O.D.) values were calculated by subtracting the mean
blank O.D. from the mean value for each sample by
using specific data obtained in the ELISA assays. The
lower limits of positivity (cut-off ) for rLiHyV and A2
proteins, as well as to SLA L. infantum, were established
for optimal sensitivity and specificity using the Receiver
Operator Curve (ROC curves). The accuracy was evalu-
ated according to the area under the curve (AUC) rela-
tive to the ROC curve, with a 95 % confidence interval
(CI95%). The ROC curves were plotted with the values
from serum samples from dogs presenting CVL, when
compared to those from the control groups (T. cruzi-,
E. canis- or B. canis-infected, Leish-Tec®-immunized
animals, and non-infected dogs), according to a sick/
non-sick rating method. Statistical analysis of the data
from vaccinated and/or infected animals was performed
by one-way analysis of variance (ANOVA), following
Bonferroni’s post-test for multiple comparisons between
the groups. Results are shown as dotted or bars graphs,
where mean ± standard deviation (SD) of each experi-
mental group is shown. Differences were considered
significant when P < 0.05.
Results and discussion
Serodiagnosis of CVL using the rLiHyV protein
Serological tests are currently recommended for the labora-
torial diagnosis of CVL. Some of them, such as IFAT and
ELISA, can present low sensitivity to detect cases from
animals presenting low levels of antileishmanial antibodies,
also their specificity can be hampered due tocross-reaction
with antibodies in sera of animals developing other path-
ologies, such as Chagas’ disease, ehrlichiose, and babesiosis
[35, 36]. In addition, in Brazil, there are two commercial
vaccines against CVL, Leishmune® [37] and Leish-Tec® [15]
and, although protective, they can induce seroconversion in
the immunized animals, causing them to be classified as
false-positive in the serological assays performed [9, 38].
In the present study, a non-described Leishmania-specific
protein was fused as a recombinant protein to an N-
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HyV protein was purified and evaluated for the serodiagno-
sis of CVL. In the results, it was possible to verify that
rLiHyV was recognized by all sera from VL dogs. In con-
trast, antibodies from T. cruzi-, E. canis- or B. canis-in-
fected dogs, from Leish-Tec®-vaccinated animals or those of
non-infected dogs; did not react with the recombinant pro-
tein (Fig. 1a). The SLA L. infantum and rA2 protein were
used as comparative antigens. Using SLA, although all VL
dogs’ sera had been recognized, a significant cross-reactivity
was observed when sera from T. cruzi-infected animals
were evaluated (Fig. 1b). Using the A2 protein as a diagno-
sis marker [39–41], a cross-reaction was also observed
when sera of dogs experimentally infected with E. canis or
B. canis were evaluated (Fig. 1c). To determine the diagnos-
tic performance of the rLiHyV protein, ROC curves were
constructed, and it was possible to observe that this antigen
presented sensitivity and specificity values of 100 %;
whereas using SLA, these values were of 100 and 81.67 %,
respectively; and with the A2 protein, they were of 100
and 77.59 %, respectively (Fig. 1d). The number and var-
iety of sera used in the present study could be consideredFig. 4 Protection of BALB/c mice vaccinated with rLiHyV protein plus sapo
lately infected with L. infantum. The parasite burden in the liver (a), spleen
measured 10 weeks after challenge. Bars represent the mean ± standard de
the saline, saponin or rLiHyV/saponin groups were observed (a, b and c leta limiting factor. In this context, data here presented
should be taken as a proof-of-concept of the efficacy of
the proposed antigen to be employed in the serodiagnosis
of CVL, and may well serve as a reference for further as-
says. On the other hand, we believe that, after an adequate
validation, the rLiHyV protein may be promptly applied
for a sensitive and specific serodiagnosis of CVL.
Immunogenicity of LiHyV protein in BALB/c mice
In this study, the immunogenicity of rLiHyV protein, as
well as two synthetic peptides (Peptide1 and Peptide2)
covering two putative CD8+ T cell epitopes present in
the primary structure of the protein was evaluated in
BALB/c mice. Four weeks after the last vaccine dose and
before infection, the immune response elicited by the
vaccine was evaluated. Following the in vitro stimulation
with the rLiHyV protein, spleen cells derived from mice
vaccinated with rLiHyV/saponin produced significantly
higher levels of IFN-γ, IL-12, and GM-CSF after rLiHyV
stimulation, when compared to the negative control
(background medium). Although the Peptide1/saponin
and Peptide2/saponin groups had presented a high IFN-nin against Leishmania infantum infection. Mice were immunized and
(b), bone marrow (c), and lymph nodes draining the paws (d) was
viation of the groups. Statistically significant differences in relation to
ters, respectively; P < 0.05)
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was comparatively lower in relation to that observed in
the rLiHyV/saponin group. In addition, a low production
of IL-4 and IL-10 was observed in all experimental
groups (Fig. 2a).
Using the different stimulations (rLiHyV, Peptide1,
Peptide2 and SLA) in the spleen cells of mice of the
rLiHyV/saponin group; it was observed that both
Peptide1 and Peptide2 were able to induce a similar
IFN-γ production, but that was significantly lower
when compared to the levels found of this cytokine
using the recombinant protein stimulus (Fig. 2b).
Using the data collected from the specific stimulus
performed in each experimental group, the ratios between
IFN-γ/IL-4 and IFN-γ/IL-10 levels (Fig. 2c), as well as be-
tween IL-12/IL-4 and IL-12/IL-10 levels (Fig. 2d) were cal-
culated, and the results showed that mice vaccinated with
rLiHyV/saponin mounted a more pronounced Th1 re-
sponse before infection, when compared to the otherFig. 5 Analysis of cellular response and involvement of CD4+ and CD8+ T c
mice were obtained 10 weeks after challenge, and were in vitro stimulated
GM-CSF, IL-4 and IL-10 levels were measured by a capture ELISA (a). The ra
IL-12/IL-10 and IL-12/IL-4 levels (c) were calculated and also shown. Statisti
saponin groups were observed (a, b and c letters, respectively; P < 0.05). Th
rLiHyV/saponin group was evaluated (d). Statistically significant differences
antibodies were observed (a, b and c letters, respectively; P < 0.05). Bars repgroups. In the evaluation of humoral response, mice vacci-
nated with rLiHyV/saponin produced higher levels of
parasite-specific IgG1 (Fig. 3a) and IgG2a (Fig. 3b) isotype
antibodies, when compared to the control groups. The ra-
tio between the IgG2a and IgG1 levels was also calculated,
and the results showed that mice vaccinated with rLiHyV/
saponin presented a higher predominance of the IgG2a iso-
type in relation to its IgG1 levels (Fig. 3c). In this context,
it could be concluded that the immunization with rLi-
HyV/saponin induced a higher in vitro IFN-γ, IL-12
and GM-CSF production, as well as low levels of IL-4,
IL-10 and parasite-specific IgG1 antibodies in the vac-
cinated animals.
Protective efficacy against L. infantum infection
To evaluate the protective efficacy of rLiHyV protein and
its two peptides in BALB/c mice against L. infantum infec-
tion, the parasite load was estimated in the liver, spleen,
BM, and dLN of the vaccinated and infected animals,ells in the IFN-γ production after L. infantum infection. Spleen cells of
with SLA (25 μg per mL), for 48 h at 37 °C in 5 % CO2. IFN-γ, IL-12,
tios between IFN-γ/IL-10 and IFN-γ/IL-4 levels (b), as well as between
cally significant differences in relation to the saline, saponin or rLiHyV/
e involvement of CD4+ and CD8+ T cells in the IFN-γ production in the
in relation to the use of anti-IL-12, anti-CD4 or anti-CD8 monoclonal
resent the mean ± standard deviation of the groups
Fig. 6 Analysis of humoral response after L. infantum infection. Sera
samples were collected of animals, 10 weeks after infection, when
the parasite-specific IgG1 (a) and IgG2a (b) isotype levels were
evaluated. The ratios between the IgG2a and IgG1 levels were
calculated, and the bars represent the mean ± standard deviation of
the groups (c). Statistically significant differences in relation to the
saline, saponin or rLiHyV/saponin groups were observed (a, b and c
letters, respectively; P < 0.05)
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tions in the parasite burden were observed in all organs of
mice vaccinated with rLiHyV/saponin, when compared to
the other groups (Fig. 4). In this context, mice vaccinated
with rLiHyV/saponin presented reductions in the parasite
load in the liver (3.4- and 3.2-log reductions, Fig. 4a),
spleen (3.3- and 3.0-log reductions, Fig. 4b), BM (4.0- and
3.8-log reductions, Fig. 4c), and dLN (3.4- and 3.3-log
reductions, Fig. 4d), when compared to the saline and
saponin groups, respectively. Comparing the protective
efficacy of the recombinant protein and its synthetic
peptides, it was possible to verify that mice immunized
with rLiHyV/saponin presented significant reductions in
the parasite load in the liver (3.0- and 2.8-log reductions,
Fig. 4a), spleen (2.5- and 2.4-log reductions, Fig. 4b), BM
(3.6- and 3.6-log reductions, Fig. 4c), and dLN (2.9- and
2.8-log reductions, Fig. 4d), when compared to the Pep-
tide1/saponin and Peptide2/saponin groups, respectively.
These data were demonstrating that the inoculation of the
recombinant protein was able to induce better protection
than the peptide-derived vaccines.
With the advancement in recombinant DNA technology,
Leishmania spp. proteins, either species or stage-specific of
the parasites, had been evaluated as vaccine candidates
against leishmaniasis. The major advantages associated to
the use of recombinant proteins have been based in terms
of standardization, purity and yield of production [24]. On
the other hand, although whole proteins had been well-
studied [15, 18, 21, 42], the protective immunity is known
to be triggered by their CD4+ and/or CD8+ T cells epitopes
[43–45]. More recent bioinformatics approaches utilize a
number of algorithms for predicting epitopes, HLA-bind-
ing, transporter of antigen processing affinity, and prote-
asome cleavage to explore the use of these peptides with
the higher probability to be immunogenic, and inducing
protection against intracellular pathogens [46, 47]. In the
present study, a comparison of the protective efficacy be-
tween the recombinant LiHyV protein and two of its puta-
tive CD8+ T cells-specific epitopes, Peptide1 and Peptide2,
was performed. The choice to study CD8+ T cells epitopes
was based on the fact that rLiHyV protein is also a protein
expressed in the amastigote stage of L. infantum. In the
results, it was obtained that the peptide-based vaccine was
also able to reduce the parasite burden in the inoculated
animals, when compared to the saponin and saline inocu-
lated mice groups. These data may indicate the possibility
of designing peptide-based vaccines. However, the protect-
ive characteristic of these vaccines should be improved,
such as increasing the number of doses, the amount of
peptide in each dose, and even using some carrier mole-
cules [48–50]. On the other hand, employing combined
vaccines containing different peptides could optimize the
protective efficacy, when compared to the use of individ-
ual peptides [14, 24, 25, 51].
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against infection
The production of cytokines in the culture supernatants of
spleen cells was also evaluated 10 weeks after infection. In
the results, spleen cells of mice vaccinated with rLiHyV/
saponin produced higher levels of parasite-specific IFN-γ,
IL-12 and GM-CSF cytokines, than those secreted by
spleen cells of the other groups (Fig. 5a). In contrast, in
mice vaccinated with the rLiHyV/saponin, the SLA-driven
production of IL-4 and IL-10 was lower when compared to
animals that received saline or saponin (Fig. 5a). In
addition, the ratios between IFN-γ/IL-4 and IFN-γ/IL-10
levels (Fig. 5b), as well as between IL-12/IL-4 and IL-12/
IL-10 (Fig. 5c) levels demonstrated that mice vaccinated
with rLiHyV/saponin mounted a more pronounced
parasite-derived Th1 response after infection. The contri-
bution of CD4+ and CD8+ T cells and the dependence of
IL-12 production in the SLA-specific IFN-γ production of
mice immunized with rLiHyV/saponin after infection was
evaluated (Fig. 5d). The addition of anti-CD4 antibodies to
the cultures was able to significantly decrease the parasite-
specific IFN-γ production. A slight reduction was also ob-
served when the anti-CD8 monoclonal antibody was used.
These results indicate that the main production of IFN-γ is
due to the induction of a parasite-specific CD4+ T cells re-
sponse. These cells have proved to be an important source
of IFN-γ in mice vaccinated with recombinant proteins. It
is expected that these products are taken by phagocytic
cells, processed and presented associated with MHC class
II molecules, inducing a predominant CD4+ T cell response
[50]. These results do not exclude the possibility of the ex-
istence of CD8+ epitopes in this protein, as expected by the
protection observed in mice vaccinated with Peptide1 and
Peptide2. For instance, it is possible to suggest that using
the LiHyV sequence as a DNA vaccine, both CD4+ and
CD8+ T cells responses could be generating, improving the
vaccine protection based on a similar contribution of both
T cells subtypes [52].
Spleen cells derived from BALB/c mice vaccinated
with rLiHyV/saponin, when compared to the other
groups, produced higher levels of SLA-specific GM-CSF, a
cytokine related to macrophage activation and resistance
against L. major [53], L. donovani [54], and L. infantum
[16, 19, 21]. In addition, this cytokine has also played an
important role in the activation, maturation, and function
of dendritic cells [55]. The present study also showed that
immunization using rLiHyV/saponin induced a low pro-
duction of IL-4 and IL-10 after infection. Very low levels
of parasite-specific IL-10 were detected after stimulation
of spleen cells derived from vaccinated and infected mice,
although spleen cells obtained from saline and saponin
groups had showed a significantly higher production of
these cytokines. Indeed, the control of parasite-mediated
IL-10 response in mice may be critical for protectionagainst murine VL, since this cytokine is considered to be
the most important factor for inhibiting the disease pro-
gression in IL-10 deficient mice [56, 57], as well as in
animals treated with an anti-IL-10 receptor antibody [58].
In BALB/c mice, IL-4-dependent production of IgG1
antibodies is associated with disease progression caused by
L. amazonensis [32, 43, 59] and L. infantum [19, 21, 60].
For instance, BALB/c mice vaccinated with the recombin-
ant A2 protein [15, 32] or Leishmania ribosomal proteins
[16] develop low levels of parasite-specific IgG1 antibodies,
and this fact could contribute to protect the animals
against Leishmania spp. infection. In the present study,
mice that received saline or saponin presented higher para-
site-specific IgG1 antibody levels (Fig. 6a), when compared
to the other groups. On the other hand, animals vaccinated
with rLiHyV/saponin showed higher levels of specific
IgG2a antibodies (Fig. 6b), which possibly contributed to
the protective response. These animals also presented a
higher ratio between the IgG2a and IgG1 levels (Fig. 6c),
demonstrating that the recombinant protein was able to
mount a more pronounced Th1 response in the vaccinated
animals, which was maintained after L. infantum infection.
Conclusions
In the present study, a non-described Leishmania-spe-
cific protein, LiHyV, which was found to be expressed in
both promastigote and amastigote stages of L. infantum,
was successfully evaluated as a vaccine candidate against
VL. Also, the recombinant protein demonstrated to be
an effective marker for the serodiagnosis of CVL, and
may well be employed in future studies aiming both
immunological applications on leishmaniasis.
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